장용성 공캡슐 시장 : 시장 기회, 성장 촉진요인, 산업 동향 분석, 예측(2025-2034년)

The Global Enteric Empty Capsules Market was valued at USD 2.7 billion in 2024 and is estimated to grow at a CAGR of 6.9% to reach USD 5.2 billion by 2034. This surge is being driven by the increasing need for advanced drug delivery systems that ensure targeted, delayed release of active pharmaceutical and nutraceutical compounds. By shielding sensitive ingredients from stomach acidity and delivering them directly to the intestines, enteric capsules are critical for gastrointestinal medications and acid-sensitive therapies. Their versatility extends to antibiotics, antacids, and enzyme treatments, making them an essential component of modern formulations.

The rapid growth of personalized medicine and patient-centric design is further boosting demand, thanks to formulation flexibility and compatibility with diverse active ingredients. In the expanding nutraceutical arena, enteric capsules-especially HPMC-based, vegan-friendly types-are increasingly favored for probiotic, enzyme, and herbal supplement delivery. The preference for clean-label, plant-based options is prompting manufacturers to invest in silicone-free, vegetarian capsule alternatives.

The Gelatin segment generated USD 1.6 billion in 2024. Its affordability, film-forming quality, and ease of production make it the default choice for large-scale capsule manufacturing, especially where non-vegetarian formulations are acceptable. Its regulatory convenience and compatibility with a variety of APIs make it a top choice for many pharmaceutical and supplement producers.

Enteric empty capsules are employed in the antibiotic and antibacterial drugs segment, which held a 43.5% share in 2024. These capsules protect acid-sensitive antibiotics from gastric degradation, ensuring optimal absorption in the intestines. They also help minimize side effects and mask the unpleasant taste of certain medications, improving patient adherence and treatment success.

U.S. Enteric Empty Capsules Market accounted for USD 986.8 million in 2024, driven by widespread gastrointestinal conditions affecting tens of millions of people, and a robust supplement intake among adults. Regulatory clarity from agencies like the FDA and USDA supports fast-track development and adoption of pH-dependent and delayed-release capsule technologies.

Key manufacturers in this industry include Lonza, Roquette Freres, Chemcaps, Bright Pharma Caps, Qingdao Yiqing, ACG Worldwide, Natural Capsules, Yiyang Pharma, Capsuline, Shaoxing Zhongya Capsule, Fortcaps Healthcare, CapsCanada, Suheung, and Zhejiang Huili Capsules. To bolster their market position, leading manufacturers in the enteric empty capsules space are deploying several key strategies. They're investing in R&D to develop innovative capsule materials-such as HPMC and plant-based polymers-that appeal to health-conscious consumers and meet regulatory standards.

Strategic partnerships with pharmaceutical and nutraceutical firms facilitate the co-development of customized solutions tailored to specific APIs and delivery systems. Many companies are expanding production capacities and establishing facilities closer to regional hubs to improve supply chain efficiency. Emphasis on clean-label, vegan-friendly certification, and transparent manufacturing processes addresses consumer demand for ethical and safe products.

Table of Contents

Chapter 1 Methodology and Scope

• 1.1 Market scope and definitions
• 1.2 Research design
  • 1.2.1 Research approach
  • 1.2.2 Data collection methods
• 1.3 Data mining sources
  • 1.3.1 Global
  • 1.3.2 Regional/country
• 1.4 Base estimates and calculations
  • 1.4.1 Base year calculation
  • 1.4.2 Key trends for market estimation
• 1.5 Primary research and validation
  • 1.5.1 Primary sources
• 1.6 Forecast model
• 1.7 Research assumption and limitations

Chapter 2 Executive Summary

• 2.1 Industry 360⁰ synopsis
• 2.2 Key market trends
  • 2.2.1 Regional
  • 2.2.2 Product
  • 2.2.3 Application
  • 2.2.4 Capsule size
  • 2.2.5 End use
• 2.3 CXO perspectives: Strategic imperatives
  • 2.3.1 Key decision points for industry executives
  • 2.3.2 Critical success factors for market players
• 2.4 Future outlook and strategic recommendations

Chapter 3 Industry Insights

• 3.1 Industry ecosystem analysis
  • 3.1.1 Supplier landscape
  • 3.1.2 Value addition at each stage
  • 3.1.3 Factor affecting the value chain
• 3.2 Industry impact forces
  • 3.2.1 Growth drivers
    • 3.2.1.1 Increasing demand for targeted drug delivery
    • 3.2.1.2 Growing shift toward vegetarian capsule alternatives
    • 3.2.1.3 Expansion of personalized medicine solutions
    • 3.2.1.4 Advancements in capsule coating technologies
  • 3.2.2 Industry pitfalls and challenges
    • 3.2.2.1 Regulatory complexity for enteric formulations
    • 3.2.2.2 High production and coating costs
  • 3.2.3 Market opportunities
    • 3.2.3.1 Growing consumption of nutraceutical globally
    • 3.2.3.2 Increasing demand for over-the-counter medications and supplements in developing economies
• 3.3 Growth potential analysis
• 3.4 Future market trends
• 3.5 Consumer behaviour analysis
• 3.6 Regulatory landscape
  • 3.6.1 North America
  • 3.6.2 Europe
  • 3.6.3 Asia Pacific
  • 3.6.4 Latin America
  • 3.6.5 Middle East and Africa
• 3.7 Porter's analysis
• 3.8 PESTEL analysis

Chapter 4 Competitive Landscape, 2024

• 4.1 Introduction
• 4.2 Company market share analysis
• 4.3 Company matrix analysis
• 4.4 Competitive analysis of major market players
• 4.5 Competitive positioning matrix
• 4.6 Key developments
  • 4.6.1 Merger and acquisition
  • 4.6.2 Partnership and collaboration
  • 4.6.3 New product launches
  • 4.6.4 Expansion plans

Chapter 5 Market Estimates and Forecast, By Product, 2021 - 2034 ($ Mn)

• 5.1 Key trends
• 5.2 Gelatin capsules
• 5.3 Non-gelatin capsules
  • 5.3.1 HPMC (hydroxypropyl methylcellulose)
  • 5.3.2 Pullulan capsules
  • 5.3.3 Starch-based capsules
  • 5.3.4 Other non-gelatin capsules

Chapter 6 Market Estimates and Forecast, By Application, 2021 - 2034 ($ Mn)

• 6.1 Key trends
• 6.2 Antacid and antiflatulent preparations
• 6.3 Antibiotic and antibacterial drugs
• 6.4 Other applications

Chapter 7 Market Estimates and Forecast, By Capsule Size, 2021 - 2034 ($ Mn)

• 7.1 Key trends
• 7.2 Size 00
• 7.3 Size 0
• 7.4 Size 1
• 7.5 Other capsule size

Chapter 8 Market Estimates and Forecast, By End Use, 2021 - 2034 ($ Mn)

• 8.1 Key trends
• 8.2 Pharmaceutical companies
• 8.3 Nutraceutical manufacturers
• 8.4 Other end use

Chapter 9 Market Estimates and Forecast, By Region, 2021 - 2034 ($ Mn)

• 9.1 Key trends
• 9.2 North America
  • 9.2.1 U.S.
  • 9.2.2 Canada
• 9.3 Europe
  • 9.3.1 Germany
  • 9.3.2 UK
  • 9.3.3 France
  • 9.3.4 Spain
  • 9.3.5 Italy
  • 9.3.6 Netherlands
• 9.4 Asia Pacific
  • 9.4.1 China
  • 9.4.2 Japan
  • 9.4.3 India
  • 9.4.4 Australia
  • 9.4.5 South Korea
• 9.5 Latin America
  • 9.5.1 Brazil
  • 9.5.2 Mexico
  • 9.5.3 Argentina
• 9.6 Middle East and Africa
  • 9.6.1 South Africa
  • 9.6.2 Saudi Arabia
  • 9.6.3 UAE

Chapter 10 Company Profiles

• 10.1 ACG Worldwide
• 10.2 Bright Pharma Caps
• 10.3 CapsCanada
• 10.4 Capsuline
• 10.5 Chemcaps
• 10.6 Fortcaps Healthcare
• 10.7 Lonza
• 10.8 Natural Capsules
• 10.9 Qingdao Yiqing
• 10.10 Roquette Freres
• 10.11 Shaoxing Zhongya Capsule
• 10.12 Suheung
• 10.13 Yiyang Pharma
• 10.14 Zhejiang Huili Capsules